Inventor
GRANT WISHART
Inventor
GB
Overview
Patents· 10 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations37%
C07DHeterocyclic compounds37%
A61KPreparations for medical, dental or toiletry purposes19%
C07BGeneral methods of organic chemistry7%
PatentTitleYear
12,466,841Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists202512,252,488HPK1 antagonists and uses thereof202512,215,105HPK1 antagonists and uses thereof202512,202,816Compounds as NADPH oxidase inhibitors202512,071,442Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists202412,016,852Pyrrolidine glycosidase inhibitors202411,926,625HPK1 antagonists and uses thereof202411,795,165Tetrahydro-benzoazepine glycosidase inhibitors202311,685,734ATM kinase inhibitors and compositions and methods of use thereof202311,548,890HPK1 antagonists and uses thereof2023Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2023–2025Patents assigned to NIMBUS SATURN INC (6)· patent assignee history
2023–2024Patents assigned to ASCENEURON SA (2)· patent assignee history
2023Patents assigned to CHDI FOUNDATION INC (1)· patent assignee history
2023–2025Based in GB· patent location history
2025Patents assigned to CALLIDITAS THERAPEUTICS SUISSE SA (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| NIMBUS SATURN INC | 6 | 2023–2025 |
| ASCENEURON SA | 2 | 2023–2024 |
| CALLIDITAS THERAPEUTICS SUISSE SA | 1 | 2025 |
| CHDI FOUNDATION INC | 1 | 2023 |
Locations
| Location | Patents | Span |
|---|---|---|
| GB | 10 | 2023–2025 |